Investor’s Watch List: Forest City Realty Trust, Inc (FCE-A), Celgene Corporation (CELG), Merrimack Pharmaceuticals, Inc. (MACK)

Forest City Realty Trust, Inc (FCE-A) had a active trading with around 3.98M shares changing hands compared to its three month average trading volume of 1.95M. The stock traded between $20.32 and $21.32 before closing at the price of $21.19 with 3.42% change on the day. The company is currently trading 31.09% above its 52 week low of $16.43 and -12.26% below its 52 week high of $24.22. Both the RSI indicator and target price of 65.36 and $24.7 respectively, lead us to believe that it should be put on hold over the coming weeks.

Forest City Realty Trust, Inc is a real estate investment trust. It was formerly known as Forest City Enterprises, Inc. Forest City Realty Trust, Inc was founded in 1920 and is headquartered in Cleveland, Ohio.

Celgene Corporation (CELG) continued its downward trend with the stock declining -0.14% or $-0.16 to close the day at $117.08 on light trading volume of 3.97M shares, compared to its three month average trading volume of 4.89M. The Summit New Jersey 07901 based company has been outperforming the biotechnology group over the past 52 weeks, with the stock gaining 16.3%, compared to the industry which has advanced 3.08% over the same period. With RSI of 47.38, the stock should still continue to rise and get closer to its one year target estimate of $138.13, making it a hold for now.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet’s disease, atopic dermatitis, and ulcerative colitis. The company’s products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; TriNetX, Inc.; Triphase Accelerator Corporation; Nurix Inc.; Abbott; Sage Bionetworks; and PharmAkea Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Merrimack Pharmaceuticals, Inc. (MACK) shares were down in last trading by -0.61% to $3.27. It experienced lighter than average volume on day. The stock decreased in value by almost -13.95% over the past week and fell -38.42% in the past month. It is currently trading -37.22% below its 50 day moving average and -43.84% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -63.75% decrease in value from its one year high of $9.02. The RSI indicator value of 22.91, lead us to believe that it may correct downwards in the near term.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Investor’s Watch List: Merrimack Pharmaceuticals, Inc. (MACK), eBay Inc. (EBAY), Hewlett Packard Enterprise Company (HPE)

Merrimack Pharmaceuticals, Inc. (MACK) had a light trading with around 13.84M shares changing hands compared to its three month average trading volume of 3.68M. The stock traded at the price of $3.4 with -7.36% change on the day. The Cambridge Massachusetts 02139 based company is currently trading -1.73% below its 52 week low of $3.46 and -62.31% below its 52 week high of $9.02. Both the RSI indicator and target price of 25.94 and $9.67 respectively, lead us to believe that it could rise over the coming weeks.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

eBay Inc. (EBAY) continued its downward trend with the stock declining -1.63% or $-0.5 to close the day at $30.25 on active trading volume of 13.82M shares, compared to its three month average trading volume of 11.08M. The San Jose California 95125 based company has been outperforming the specialty retail, other group over the past 52 weeks, with the stock gaining 15.9%, compared to the industry which has advanced 31.4% over the same period. With RSI of 57.11, the stock should still continue to rise and get closer to its one year target estimate of $32.77, making it a hold for now.

eBay Inc. operates e-commerce platforms that connect various buyers and sellers worldwide. Its platforms enable sellers to organize and offer inventory for sale; and buyers to find and buy it virtually anytime and anywhere. The company’s Marketplace platforms include its online marketplace at ebay.com and the eBay mobile apps; and StubHub platforms comprise its online ticket platform at stubhub.com and the StubHub mobile apps, which enable fans to purchase tickets to the games, concerts, and theater shows. Its Classifieds platforms include a collection of brands, such as Mobile.de, Kijiji, Gumtree, Marktplaats, eBay Classifieds, and others that offer online classifieds and help people find whatever they are looking for in their local communities. The company platforms enable users to find, buy, sell, and pay for items through various online, mobile, and offline channels, which include retailers, distributors, liquidators, import and export companies, auctioneers, catalog and mail-order companies, classifieds, directories, search engines, commerce participants, shopping channels, and networks. eBay Inc. was founded in 1995 and is headquartered in San Jose, California.

Hewlett Packard Enterprise Company (HPE) shares were up in last trading by 1.73% to $22.95. It experienced higher than average volume on day. The stock decreased in value by almost -1.08% over the past week and fell -6.61% in the past month. It is currently trading -1.61% below its 50 day moving average and 12.05% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -7.18% decrease in value from its one year high of $24.79. The RSI indicator value of 42.31, lead us to believe that it is a hold for now.

Hewlett Packard Enterprise Company provides technology solutions to business and public sector enterprises. It operates through Enterprise Group, Software, Enterprise Services, and Financial Services segments. The Enterprise Group segment offers industry standard servers and mission-critical servers to address the array of its customers’ computing needs; converged storage solutions, including 3PAR StoreServ, StoreOnce, all-flash arrays, and software defined and StoreVirtual products; wireless local area network equipment, mobility and security software, switches, routers, and network management products; and support and technology consulting services. The Software segment offers software to capture, store, explore, analyze, protect, and share information and insights within and outside organizations; HP Vertica, an analytics database technology for machine, structured, and semi-structured data; and HP IDOL, an analytics tool for human information, as well as solutions for archiving, data protection, eDiscovery, information governance, and enterprise content management. This segment also provides application delivery management, enterprise security, and IT operations management software products. The Enterprise Services segment offers technology consulting, outsourcing, and support services in infrastructure, applications, and business process domains within traditional and strategic enterprise service (SES) offerings, which include analytics and data management, security, and cloud services. The Financial Services segment provides leasing, financing, IT consumption and utility programs, and asset management services. The company markets and sells its products through resellers, distribution partners, original equipment manufacturers, independent software vendors, systems integrators, and advisory firms. Hewlett Packard Enterprise Company is headquartered in Palo Alto, California.

 

3 Stocks to Watch For: Advanced Micro Devices, Inc. (AMD), EnteroMedics Inc. (ETRM), Merrimack Pharmaceuticals, Inc. (MACK)

Advanced Micro Devices, Inc. (AMD) saw its value increase by 1.5% as the stock gained $0.17 to finish the day at a closing price of $11.49. The stock was lighter in trading and has fluctuated between $1.75-$12.42 per share for the past year. The shares are up by 70.22% in the past three months and up by 129.34% over the past six months. It is currently trading 3.03% above its 20 day moving average and 25.45% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $8.88 a share over the next twelve months. The current relative strength index (RSI) reading is 66.65.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily include x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products. It provides x86 microprocessors for desktop PCs under the AMD A-Series, AMD E-Series, AMD FX CPU, AMD Athlon CPU and APU, AMD Sempron APU and CPU, and AMD Pro A-Series APU brands; and microprocessors for notebook and 2-in-1s under the AMD A-Series, AMD E-Series, AMD C-Series, AMD Z-Series, AMD FX APU, AMD Phenom, AMD Athlon CPU and APU, AMD Turion, and AMD Sempron APU and CPU brands. The company also offers chipsets with and without integrated graphics features for desktop, notebook PCs, and servers, as well as controller hub-based chipsets for its APUs under the AMD brand; and AMD PRO mobile and desktop processors. In addition, it provides discrete desktop graphics products and discrete GPUs for notebooks under the AMD Radeon brand; professional graphics products under the AMD FirePro brand; and customer-specific solutions based on AMD’s CPU, GPU, and multi-media technologies. Further, the company offers microprocessors for server platforms under the AMD Opteron; embedded processor solutions for interactive digital signage, casino gaming, and medical imaging under the AMD Opteron, AMD Athlon, AMD Sempron, AMD Geode, AMD R-Series, and G-Series brands; and semi-custom SoC products that power the Sony Playstation 4 and Microsoft Xbox One game consoles. Advanced Micro Devices, Inc. sells its products through its direct sales force, independent distributors, and sales representatives. The company serves original equipment manufacturers, original design manufacturers, system builders, and independent distributors. Advanced Micro Devices, Inc. was founded in 1969 and is headquartered in Sunnyvale, California.

EnteroMedics Inc. (ETRM) shares were up in last trading by 92.6% to $17.7. It experienced higher than average volume on day. The stock increased in value by almost 785% over the past week and grew 32677.78% in the past month. It is currently trading 3204.82% above its 50 day moving average and 3926.84% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a 81.54% increase in value from its one year high of $132.3. The RSI indicator value of 97.41, lead us to believe that it may reverse gains in the near term.

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Merrimack Pharmaceuticals, Inc. (MACK) opening the day at $4.8. The company has seen its stock decrease in value by -10.05% so far this year. The stock was up close to 1.94% on active volume in last trading session and closed at $3.67 per share. After the recent gain, the stock is currently holding -59.31% below its 52 week high of $9.02 and 6.07% above its 12-month low of $3.46. The shares are down by over -33.03% in the last three months, and the RSI indicator value of 31.49 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Stocks Under Review: Merrimack Pharmaceuticals, Inc. (MACK), JetBlue Airways Corporation (JBLU), Boston Scientific Corporation (BSX)

Merrimack Pharmaceuticals, Inc. (MACK) continued its downward trend with the stock declining -5.26% or $-0.2 to close the day at $3.6 on active trading volume of 7.75M shares, compared to its three month average trading volume of 3.14M. The Cambridge Massachusetts 02139 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -45.78%, compared to the industry which has dropped -1.38% over the same period. With RSI of 28.68, the stock should still continue to rise and get closer to its one year target estimate of $9.67, making it a hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

JetBlue Airways Corporation (JBLU) retreated with the stock falling -1.98% or $-0.44 to close at $21.83 on active trading volume of 7.68M compared its three months average trading volume of 5.98M. The Long Island City New York 11101 based company operating under the Regional Airlines industry has been trending up for the last 52 weeks, with the shares price now 5.05% up for the period and down by -2.63% so far this year. With price target of $25.42 and a 47.9% rebound from 52-week low, JetBlue Airways Corporation has plenty of upside potential, making it a hold with a view buy.

JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 25 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 Embraer E190 aircrafts. It also served 93 destinations in 28 states in the United States, the District of Columbia, the Commonwealth of Puerto Rico, the U.S. Virgin Islands, and 19 countries in the Caribbean and Latin America. JetBlue Airways Corporation was founded in 1998 and is based in Long Island City, New York.

Boston Scientific Corporation (BSX) managed to rebound with the stock climbing 0.45% or $0.1 to close the day at $22.15 on lower than average trading volume of 7.55M shares, compared to its three month average trading volume of 8.46M. The Marlborough Massachusetts 01752 based company has been underperforming the medical appliances & equipment companies by -5.5769% for last three months and its recent losses have trimmed gains to 2.4% YTD, versus the medical appliances & equipment industry which is up 1.86% for the same period. The RSI of 63.35 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

 

Traders Recap: Merrimack Pharmaceuticals, Inc. (MACK), Bonanza Creek Energy Inc. (BCEI), The Blackstone Group L.P. (BX)

Merrimack Pharmaceuticals, Inc. (MACK) failed to extend gains with the stock declining -7.09% or $-0.29 to close the day at $3.8 on higher than average trading volume of 7.73M shares, compared to its three month average trading volume of 3.09M. The Cambridge Massachusetts 02139 based company has been outperforming the biotechnology companies by -36.2768% for last three months and its recent losses have pulled the stock down -6.86% YTD, versus the biotechnology industry which is up 2.45% for the same period. The RSI of 30.87 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Bonanza Creek Energy Inc. (BCEI) had a active trading with around 7.66M shares changing hands compared to its three month average trading volume of 3.24M. The stock traded between $1.25 and $1.63 before closing at the price of $1.55 with 12.32% change on the day. The Denver Colorado 80202 based company is currently trading 158.33% above its 52 week low of $0.6 and -70.97% below its 52 week high of $4.7. Both the RSI indicator and target price of 55.88 and $1.03 respectively, lead us to believe that it should be put on hold over the coming weeks.

Bonanza Creek Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of onshore oil and associated liquids-rich natural gas in the United States. The company’s oil and liquids weighted assets are located primarily in the Wattenberg Field in Colorado; and the Dorcheat Macedonia Field in southern Arkansas. It also owns and operates oil-producing assets in the North Park Basin in Colorado; and the McKamie Patton Field in Southern Arkansas. Bonanza Creek Energy Inc. was founded in 2010 and is headquartered in Denver, Colorado.

The Blackstone Group L.P. (BX) traded within a range of $29.7 to $30.63 after opening the day at $29.85. The company has seen its stock increase in value by 12.54% so far this year. The stock was up close to 2.08% on active volume in last trading session and closed at $30.42 per share. After the recent gain, the stock is currently holding -0.2% below its 52 week high of $30.63 and 45.25% above its 12-month low of $22.31. The shares are up by over 23.07% in the last three months, and the RSI indicator value of 70.32 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.

The Blackstone Group L.P. is a publicly owned hedge fund sponsor. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations, retirees, sovereign wealth funds, and institutional and individual investors. The firm manages separate client focused portfolios for its clients. It launches fixed income mutual funds. The firm also launches and manages private equity funds, real estate funds, funds of hedge funds, and credit-focused funds for its clients. It invests in private equity, public equity, fixed income, and alternative investment markets. The Blackstone Group L.P. was founded in 1985 and is based in New York, New York with additional offices in London, United Kingdom, Hong Kong, Beijing, China, Dubai, UAE, Dusseldorf, Germany, Los Angeles, Santa Monica, Mexico City, Mexico, Paris, France, Sao Paulo, Brazil, Seoul, Korea, Shanghai, China, Singapore, Sydney, Australia, Copenhagen, Denmark, and Tokyo, Japan.

 

Stocks on Trader’s Radar: Visa Inc. (V), Merrimack Pharmaceuticals, Inc. (MACK), Wal-Mart Stores, Inc. (WMT)

Visa Inc. (V) continued its upward trend with the stock climbing 0.82% or $0.65 to close the day at $80.15 on active trading volume of 8.02M shares, compared to its three month average trading volume of 10.38M. The San Francisco California 94128 based company has been outperforming the credit services group over the past 52 weeks, with the stock gaining 5.89%, compared to the industry which has advanced 14.56% over the same period. With RSI of 58.75, the stock should still continue to rise and get closer to its one year target estimate of $94.19, making it a hold for now.

Visa Inc. operates as a payments technology company worldwide. The company facilitates commerce through the transfer of value and information among consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It operates VisaNet, a processing network that enables authorization, clearing, and settlement of payment transactions; and offers fraud protection for account holders and assured payment for merchants. The company also offers gateway services for merchants to accept, process, and reconcile payments; manage fraud; and safeguard payment security online, as well as processing services for participating issuers of visa debit, prepaid, and ATM payment products. In addition, it provides digital products, including Visa Checkout that offers consumers an expedited and secure payment experience for online transactions; and Visa Direct, a push payment product platform, which facilitates payer-initiated transactions that are sent directly to the Visa account of the recipient, as well as Visa token service that replaces the card account numbers from the transaction with a token. Further the company offers corporate (travel) and purchasing card products, as well as value-added services. It provides its services under the Visa, Visa Electron, Interlink, V PAY, and PLUS brands. The company was incorporated in 2007 and is headquartered in San Francisco, California.

Merrimack Pharmaceuticals, Inc. (MACK) climbed 2.25% during last trading as the stock added $0.09 to finish the day at $4.09 with about 7.95M shares changing hands, compared to its three month average trading volume of 3.04M. The $531.41M market cap company, which fluctuated between $3.96 and $4.25 during the day, currently situated 4.87% above its 52 week low of $3.9 and -54.66% away from its one year high of $9.02. The RSI of 35.6 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Wal-Mart Stores, Inc. (WMT) saw its value increase by 0.58% as the stock gained $0.4 to finish the day at a closing price of $69.06. The stock was lighter in trading and has fluctuated between $60.2-$75.19 per share for the past year. The shares, which traded within a range of $68.6 to $69.63 during the day, are down by -3.06% in the past three months and down by -5.13% over the past six months. It is currently trading -1.83% below its 20 day moving average and -1.24% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $74.59 a share over the next twelve months. The current relative strength index (RSI) reading is 42.48. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Wal-Mart Stores, Inc. operates retail stores in various formats worldwide. It operates through three segments: Walmart U.S., Walmart International, and Sam’s Club. The company operates discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, cash and carry stores, home improvement stores, specialty electronics stores, apparel stores, drug stores, convenience stores, and membership-only warehouse clubs; and retail Websites, such as walmart.com and samsclub.com. It offers grocery products, including meat, produce, natural and organics, deli and bakery, dairy, frozen foods, alcoholic and nonalcoholic beverages, floral and dry grocery, as well as consumables, such as health and beauty aids, baby products, household chemicals, paper goods, and pet supplies; and health and wellness products, which include pharmacy, optical services, clinical services, over-the-counter drugs, and other medical products. The company also provides electronics, toys, cameras and supplies, photo processing services, cellular phones, cellular service plan contracts and prepaid service, movies, music, video games, and books; stationery, automotive, hardware and paint, and sporting goods, as well as fabrics, crafts, and seasonal merchandise; apparel for women, girls, men, boys, and infants, as well as shoes, jewelry, and accessories; and home furnishings, housewares and small appliances, bedding, home decor, outdoor living, and horticulture products. The company also provides fuel and financial services and related products, including money orders, prepaid cards, wire transfers, money transfers, check cashing, and bill payment. In addition, it offers brand name merchandise, including hardgoods, softgoods, and selected private-label items, such as Member’s Mark. As of June 20, 2016, it operated 11,527 stores under 63 banners in 28 countries and e-commerce Websites in 11 countries. Wal-Mart Stores, Inc. was founded in 1945 and is headquartered in Bentonville, Arkansas.

 

3 Stocks in Focus: Community Health Systems, Inc. (CYH), Merrimack Pharmaceuticals, Inc. (MACK), CBS Corporation (CBS)

Community Health Systems, Inc. (CYH) climbed 3.94% during last trading as the stock added $0.22 to finish the day at $5.81 with about 3.57M shares changing hands, compared to its three month average trading volume of 5.77M. The $678.26M market cap company, which fluctuated between $5.41 and $5.81 during the day, currently situated 40% above its 52 week low of $4.15 and -74.25% away from its one year high of $21.38. The RSI of 57.15 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Community Health Systems, Inc., together with its subsidiaries, owns, leases, and operates general acute care hospitals in the United States. It offers general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric, and rehabilitation services, as well as skilled nursing and home care services. The company also provides outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers, ambulatory surgery centers, and home health and hospice agencies. In addition, it offers management and consulting services to non-affiliated general acute care hospitals. As of February 15, 2016, the company owned, leased, or operated 195 affiliated hospitals in 29 states with approximately 30,000 licensed beds. Community Health Systems, Inc. was founded in 1985 and is headquartered in Franklin, Tennessee.

Merrimack Pharmaceuticals, Inc. (MACK) dropped $-0.08 to close the day at a new closing price of $4, a -1.96% decrease in value from its previous closing price that moved the stock -0.74% below its 52 week low of $3.9. A total of 3.56M shares exchanged hands during the day compared with its three month average trading volume of 3.12M. The stock, currently situated -55.65% below its 52 week high. The stock is down by -21.57% in the past one month and down by -33.77% over the past three months. With a one year target estimate of $9.67 and RSI of 32.13, the stock still has upside potential, making it a hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

CBS Corporation (CBS) had a light trading with around 3.55M shares changing hands compared to its three month average trading volume of 4.51M. The stock traded between $63.81 and $65.7 before closing at the price of $64.39 with 1.21% change on the day. The New York New York 10019 based company is currently trading 57.59% above its 52 week low of $41.36 and -1.08% below its 52 week high of $65.7. Both the RSI indicator and target price of 65.7 and $66.13 respectively, lead us to believe that it should be put on hold over the coming weeks.

CBS Corporation operates as a mass media company worldwide. The company operates through four segments: Entertainment, Cable Networks, Publishing, and Local Broadcasting. The Entertainment segment distributes a schedule of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and distributes programming, including series, specials, news, and public affairs; operates online content networks for information and entertainment; and produces, acquires, and distributes theatrical motion pictures. The Cable Networks segment offers subscription program services, such as original series, theatrical feature films, documentaries, boxing and other sports-related programming, and special events; and owns and operates multiplexed channels. This segment also owns and manages Smithsonian Networks, which operates a channel featuring cultural, historical, scientific, and educational programs; and operates a CBS Sports Network, a 24-hour cable program service that provides college sports and related content. The Publishing segment publishes and distributes adult and children’s consumer books in printed, digital, and audio formats; and develops special imprints and publishes titles based on the products, as well as that of third parties and distributes products for other publishers. It also delivers content; and promotes its products on its Websites, social media, and general Internet sites, as well as those related to individual titles. The Local Broadcasting segment owns 30 broadcast television stations; owns and operates 117 radio stations in 26 U.S. markets and related online properties; and operates local digital properties in various U.S. markets that combine the company’s television and radio local media brands online to offer the latest news, traffic, weather, and sports information, as well as local discounts, directories, and reviews for local community. CBS Corporation was founded in 1986 and is headquartered in New York, New York.

 

Stocks Roundup: The Interpublic Group of Companies, Inc. (IPG), NorthStar Realty Finance Corp. (NRF), Merrimack Pharmaceuticals, Inc. (MACK)

The Interpublic Group of Companies, Inc. (IPG) retreated with the stock falling -0.97% or $-0.23 to close at $23.41 on light trading volume of 1.99M compared its three months average trading volume of 4.26M. The New York New York 10022 based company operating under the Advertising Agencies industry has been trending up for the last 52 weeks, with the shares price now 3.22% up for the period and up by 3.22% so far this year. With price target of $26 and a 21.42% rebound from 52-week low, The Interpublic Group of Companies, Inc. has plenty of upside potential, making it a hold with a view buy.

The Interpublic Group of Companies, Inc. provides advertising and marketing services worldwide. It operates through two segments, Integrated Agency Networks and Constituency Management Group. The company offers consumer advertising, digital marketing, communications planning and media buying, public relations, and specialized communications disciplines. It also provides various diversified services, including public relations, meeting and event production, sports and entertainment marketing, corporate and brand identity, and strategic marketing consulting. The company’s brands comprise McCann, MullenLowe, IPG Mediabrands, Carmichael Lynch, Deutsch, Hill Holliday, and The Martin Agency, as well as Foote, Cone & Belding. The company was formerly known as McCann-Erickson Incorporated and changed its name to The Interpublic Group of Companies, Inc. in January 1961. The Interpublic Group of Companies, Inc. was founded in 1902 and is headquartered in New York, New York.

NorthStar Realty Finance Corp. (NRF) had a active trading with around 1.98M shares changing hands compared to its three month average trading volume of 1.91M. The stock traded between $15 and $15.17 before closing at the price of $15.15 with 0.13% change on the day. The New York New York 10022 based company is currently trading 103.36% above its 52 week low of $8.38 and -2.88% below its 52 week high of $17.13. Both the RSI indicator and target price of  and $17.67 respectively, lead us to believe that it could rise over the coming weeks.

Merrimack Pharmaceuticals, Inc. (MACK) saw its value decrease by -0.24% as the stock dropped $-0.01 to finish the day at a closing price of $4.08. The stock was lighter in trading and has fluctuated between $4.03-$9.02 per share for the past year. The shares are down by -35.75% in the past three months and down by -26.49% over the past six months. It is currently trading -18.6% below its 20 day moving average and -24.98% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $9.67 a share over the next twelve months. The current relative strength index (RSI) reading is 32.8.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Stock’s Trend Analysis Report: Merrimack Pharmaceuticals, Inc. (MACK), Gramercy Property Trust, Inc. (GPT), CenterPoint Energy, Inc. (CNP)

Merrimack Pharmaceuticals, Inc. (MACK) fell -2.85% during last trading as the stock lost $-0.12 to finish the day at $4.09 with about 1.64M shares changing hands, compared to its three month average trading volume of 3.17M. The $511.86M market cap company, currently situated -0.97% below its 52 week low of $4.04 and -54.66% away from its one year high of $9.02. The RSI of 32.94 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Gramercy Property Trust, Inc. (GPT) gained $0.17 to close the day at a new closing price of $8.97, a 1.93% increase in value from its previous closing price that moved the stock 43.28% above its 52 week low of $6.5. A total of 1.64M shares exchanged hands during the day compared with its three month average trading volume of 3.73M. The stock, which fluctuated between $8.81 and $8.99 during the day, currently situated -9.54% below its 52 week high. The stock is down by -2.29% in the past one month and down by -6.95% over the past three months. With a one year target estimate of $26.91 and RSI of 51.29, the stock still has upside potential, making it a hold for now.

Gramercy Property Trust, Inc. is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It makes investments in industrial and office properties to create its portfolio. The firm was formerly known as Gramercy Capital Corp. Gramercy Property Trust Inc was founded in 2004 and is based in New York City with additional offices in St. Louis, Missouri and Jenkintown, Pennsylvania.

CenterPoint Energy, Inc. (CNP) had a light trading with around 1.63M shares changing hands compared to its three month average trading volume of 3.52M. The stock traded between $24.48 and $24.78 before closing at the price of $24.73 with 1.19% change on the day. The Houston Texas 77002 based company is currently trading 58.49% above its 52 week low of $16.38 and -1% below its 52 week high of $24.98. Both the RSI indicator and target price of 61.83 and $24.5 respectively, lead us to believe that it should be put on hold over the coming weeks.

CenterPoint Energy, Inc. operates as a public utility holding company in the United States. The company’s Electric Transmission & Distribution segment offers electric transmission and distribution services to retail electric providers, municipalities, electric cooperatives, and other distribution companies. As of December 31, 2015, this segment owned 28,474 pole miles of overhead distribution lines and 3,723 circuit miles of overhead transmission lines; 23,120 circuit miles of underground distribution lines and 26 circuit miles of underground transmission lines; and 232 substations with a capacity of 58,674 megavolt amperes. Its Natural Gas Distribution segment sells regulated intrastate natural gas; provides natural gas transportation and storage services for residential, commercial, industrial, and transportation customers; and offers unregulated services comprising residential appliance repair and maintenance services, as well as sells heating, ventilating and air conditioning equipment. This segment owned approximately 74,000 linear miles of natural gas distribution mains. The company’s Energy Services segment provides physical natural gas supplies primarily to commercial and industrial customers, and electric and gas utilities; natural gas management services; and physical delivery services, as well as procures and optimizes transportation and storage assets. It owns and operates approximately 200 miles of intrastate pipelines; and leases transportation capacity on various interstate and intrastate pipelines, and storage. Its Midstream Investments segment provides gathering, processing, compression, treating, dehydration, and natural gas liquids fractionation for producer customers. This segment had approximately 12,400 miles of gathering pipelines, 7,900 miles of interstate pipelines, and approximately 2,300 miles of intrastate pipelines. The company was founded in 1882 and is headquartered in Houston, Texas.

 

3 Notable Runners: Merrimack Pharmaceuticals, Inc. (MACK), Celgene Corporation (CELG), Juno Therapeutics, Inc. (JUNO)

Merrimack Pharmaceuticals, Inc. (MACK) continued its downward trend with the stock declining -0.71% or $-0.03 to close the day at $4.21 on lower than average trading volume of 1.86M shares, compared to its three month average trading volume of 3.19M. The Cambridge Massachusetts 02139 based company has been underperforming the biotechnology companies by -32.0917% for last three months and its recent losses have pulled the stock down -46.71% YTD, versus the biotechnology industry which is up 3.4% for the same period. The RSI of 33.83 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Celgene Corporation (CELG) had a light trading with around 1.85M shares changing hands compared to its three month average trading volume of 4.73M. The stock traded between $116.94 and $118.47 before closing at the price of $117.29 with -0.53% change on the day. The Summit New Jersey 07901 based company is currently trading 26.05% above its 52 week low of $93.05 and -7.65% below its 52 week high of $127. Both the RSI indicator and target price of 54.54 and $138.04 respectively, lead us to believe that it should be put on hold over the coming weeks.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet’s disease, atopic dermatitis, and ulcerative colitis. The company’s products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; TriNetX, Inc.; Triphase Accelerator Corporation; Nurix Inc.; Abbott; Sage Bionetworks; and PharmAkea Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Juno Therapeutics, Inc. (JUNO) traded within a range of $18.75 to $19.46 after opening the day at $19.44. The company has seen its stock decrease in value by -56.7% so far this year. The stock was down close to -2.21% on light volume in last trading session and closed at $19.04 per share. After the recent fall, the stock is currently holding -61.71% below its 52 week high of $49.72 and 8.68% above its 12-month low of $17.52. The shares are down by over -39.17% in the last three months, and the RSI indicator value of 43.03 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company’s additional product candidates comprise CD22, a cell surface protein expressed on B lymphocytes; CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein that is in Phase I/II clinical trials to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. Juno Therapeutics, Inc. has collaboration agreements with Celgene Corporation, Editas Medicine, Inc., Fate Therapeutics, Inc., MedImmune Limited, and Memorial Sloan Kettering Cancer Center. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.